Definitive Contract 75N91020C00030
Award Date
9/8/20
Potential Completion Date
9/7/21
Potential Value
$399K
Federal Agency
National Cancer Institute
Awardee
Indee. Inc.
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Albany, CA 94710, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
6
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed
Similar Awards
This $1,999,646 firm fixed price definitive contract was awarded by the National Cancer Institute to Indee Inc., a biotechnology startup that develops a non-viral delivery platform called Hydropore for engineered cell therapies. The contract, which was set aside for total small businesses, is for research and development services focused on a microfluidic vortex shedding method to enable efficient genetic modification of cells for use in cell-based immunotherapies. This contract builds upon...
This SBIR Phase I contract was awarded by the National Institutes of Health's National Cancer Institute to Cellfe Inc. for $358,930. The contract is for the period of September 8, 2020 through June 7, 2021 and involves research and development of a microfluidic transfection platform for rapid manufacturing of mRNA CAR lymphocyte products. The solicitation sought proposals to conduct R&D in support of NIH and CDC agency missions, including alternatives to cell culture materials and cancer...
This Small Business Innovation Research (SBIR) Phase I contract, valued at $399,674, was awarded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), to Inso Biosciences Inc., a small biotechnology startup. The contract supports the research and development of advanced sample processing platforms for downstream single-cell multi-omic analysis. This work aligns with the NIH and Centers for Disease Control and Prevention (CDC) mission to develop medical...
This firm fixed price contract for $455,000 was awarded by the National Institutes of Health National Cancer Institute to Nvigen Inc. of San Jose, California. The contract is for research under SBIR Phase II topic 403 to develop highly accurate single cell sequencing technologies with spatial resolution capabilities for cancer research applications. The work directly responds to the solicitation seeking proposals in cancer imaging, spatial sequencing, intra-tumor sensing, and other related...
<p>This is a $299,999.00 Firm Fixed Price contract awarded by the National Cancer Institute, a civilian agency, to Innogenomics Technologies, L.L.C., a minority-owned small business, under the Small Business Innovation Research (SBIR) Program Phase I. The contract is for research and development in the area of biomedical (basic research). It was awarded on September 22, 2015 with a final completion date of March 21, 2017. The contract has a total small business set-aside designation.</p>
This is a $399,062 firm-fixed-price SBIR Phase I contract awarded by the National Cancer Institute (NCI) to Avoneaux Medical Institute, LLC for the development of spatial micro-purification technology. The contract was set aside for small businesses and is part of the NCI's broader SBIR program, which funds research and development in support of the NIH and CDC's mission needs. The original solicitation sought proposals on a range of cancer-related topics, including alternatives to cell...
This $400,000 Small Business Innovation Research (SBIR) Phase I contract was awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Amplifidx Inc., a woman-owned small business. The contract supports the development of cancer prevention and diagnosis technologies for low-resource settings over a two-year period. This award aligns with NCI's mission to support innovative medical device research and development by small businesses. As a SBIR...
This is a Small Business Innovation Research (SBIR) Program Phase I contract awarded by the National Cancer Institute (NCI) to Biofluidica, Inc., a for-profit organization located in Baton Rouge, Louisiana. The contract has a ceiling value of $199,517.00 and is a Firm Fixed Price Definitive Contract. The contract was awarded on September 30, 2010 with an ultimate completion date of August 29, 2011. As an SBIR Phase I contract, this award supports early-stage research and development efforts.
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Synbal, Inc., a small business located in La Costa, California. The contract, valued at $2,300,000.00, is for the "Development and Validation of Non-Mouse Reagents to Enable Preclinical Development of Novel Therapeutics" under the "MOONSHOT" initiative. The contract was set aside for small businesses...
This $454,751 firm fixed price Small Business Innovation Research (SBIR) Phase I contract was awarded to Enrich Biosystems Inc. by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH). The 24-month research project will develop advanced sample processing platforms for downstream single-cell multi-omic analysis to support biomedical research and precision medicine efforts. This contract is set aside for small businesses and builds on Enrich Biosystems' prior SBIR...